ABSTRACT
Background Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is estimated to have caused more than 18 million deaths worldwide as of end-May 2022.
Methods COVIDENCE UK is a longitudinal population-based study that investigates risk factors for, and impacts of, COVID-19 in UK residents aged ≥16 years. A unique feature is the capacity to support trial-within-cohort studies to evaluate interventions for prevention of COVID-19 and other acute respiratory illnesses. Participants complete a detailed online baseline questionnaire capturing self-reported information relating to their socio-demographic characteristics, occupation, lifestyle, quality of life, weight, height, longstanding medical conditions, medication use, vaccination status, diet and supplemental micronutrient intake. Follow-up on-line questionnaires capturing incident symptoms of COVID-19 and other acute respiratory infections, incident swab test-confirmed COVID-19, doses of SARS-CoV-2 vaccine received, and quality of life are completed at monthly intervals.
Results The study was launched on 1st May 2020 and closed to recruitment on 6th October 2021. A total of 19,981 participants enrolled and consented to 5-year follow-up with medical record linkage. Their mean age was 59.1 years (range 16.0 to 94.4 years), 70.2% were female, and 93.7% identified their ethnic origin as White. Analyses conducted to date have provided key insights into risk factors for SARS-CoV-2 infection and COVID-19 disease, determinants of SARS-CoV-2 vaccine immunogenicity and efficacy, and impacts of COVID-19 on health economic outcomes. The cohort has also supported conduct of a Phase 3 randomised trial-within-cohort study (CORONAVIT) evaluating implementation of a test-and-treat approach to correcting sub-optimal vitamin D status on incidence and severity of acute respiratory infections, including COVID-19.
Conclusions The COVIDENCE UK dataset represents a valuable resource containing granular information on factors influencing susceptibility to, and impacts of, COVID-19 in UK adults. Researchers wishing to access anonymised participant-level data should contacting the corresponding author for further information.
INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, Hubei Province, China in December 2019.1 The World Health Organization (WHO) declared COVID-19 a pandemic on 11th March 2020.2 The disease is estimated to have caused more than 18 million deaths worldwide as of end-May 2022.3
Hospital-based studies reported risk factors for severe and fatal COVID-19 at an early stage of the pandemic.4,5 However, at this time we identified a need for population-based longitudinal studies to complement research conducted in secondary and tertiary care by identifying risk factors for developing predominantly mild/moderate COVID-19 that did not present to hospital. We considered this to be an important goal, both from a public health perspective (as mild/moderate disease may result in transmission to individuals who are at risk of more severe disease)6 and from a biological perspective (since understanding susceptibility factors can provide insights into pathogenesis).7 At the time, there was also a lack of longitudinal studies designed to characterise the natural history and sequelae of COVID-19 that did nor precipitate hospitalisation, and to evaluate the impact of non-hospitalised COVID-19 on adults’ physical and mental health over the longer term. Furthermore, we wished to establish a platform from which to conduct Phase 3 randomised controlled trials of non-pharmaceutical interventions for prevention of COVID-19 and other acute respiratory infections using Trials within Cohorts methodology.8 We therefore established a national prospective population-based longitudinal study of COVID-19 in UK adults, which we named COVIDENCE UK (https://www.qmul.ac.uk/covidence/about-the-covidence-uk-study/).
COVIDENCE UK is sponsored by, and located at, Queen Mary University of London. It was funded by Barts Charity (ref MGU0466); approved by Leicester South Research Ethics Committee (ref 20/EM/0117); and prospectively registered with ClinicalTrials.gov (NCT04330599). Enrolment opened on 1st May 2020 and closed on 6th October 2021.
METHODS
Participants were invited to complete online follow-up questionnaires at monthly intervals. Cumulative totals of those who have completed monthly questionnaires, and proportions of those completing monthly questionnaires after being invited to do so are presented in Figures 1B and 1C, respectively. A total of 1,593 (8.0%) participants have withdrawn from the study to date. Table 2 compares characteristics of participants remaining in the cohort to those of participants who have withdrawn. Increased risk of withdrawal was associated with younger vs. older age, male vs. female sex, Asian/Asian British vs. White ethnic origin and lower vs. higher educational attainment.
A, Cumulative number of baseline questionnaire completions, by month B, Cumulative number of monthly questionnaire completions, by month C, Proportion of participants who completed a monthly questionnaire following invitation to do so, by month
Table 3 presents a high-level summary of key variables for which data are available, along with details relating to the sources of these data. Full details of questions in baseline and monthly questionnaires are presented in the Supplementary Appendix.
RESULTS
Baseline characteristics of the 19,981 participants who enrolled in the cohort and completed the baseline questionnaire are presented in Table 1: mean age was 59.1 years (range 16.0 to 94.4 years), 70.2% were female, 87.7% lived in England, and 93.7% identified their ethnic origin as White. Participants were recruited following a national media campaign with publicity relating to the study appearing in print and online newspapers, radio, television, social media and online advertising; the timeline for participant accrual is illustrated in Figure 1A. Heatmaps illustrate a high degree of overlap between participants’ area of residence (Figure 2A) and the location of COVID-19 cases notified to UK public health authorities (Figure 2B).
A, heatmap of COVIDENCE UK participants’ location of residence by postcode. B, heatmap of cumulative COVID-19 notifications in the UK, by postcode, from https://coronavirus.data.gov.uk/details/download (download dated June 10, 2022).
Key findings to date include the following:
Asian/Asian British ethnicity was associated with increased odds both of serologically confirmed SARS-CoV-2 infection and of developing swab test-confirmed COVID-19, after rigorous adjustment for potential confounders including socioeconomic status, presence of comorbidities and multiple social and environmental factors influencing exposure to SARS-CoV-2.7,9 Participants of Asian/Asian British origin also had higher convalescent titres of combined IgG, IgA and IgM antibodies to the SARS-CoV-2 spike protein following infection (after adjustment for multiple potential confounders including disease severity) and higher titres of the same antibodies after SARS-CoV-2 vaccination (after adjustment for multiple potential confounders including pre-vaccination anti-S titres).9,10 Taken together, these findings highlight the need to investigate potential biological determinants of ethnic variation in susceptibility to, and severity of, COVID-19.
Similarly, higher body mass index was found to associate independently with increased susceptibility to SARS-CoV-2 infection and COVID-19, and higher titres of anti-S antibodies following COVID-19 and vaccination against SARS-CoV-2.7,9,10 The mechanisms underlying these associations are also worthy of investigation.
By contrast, we found that several factors associating with COVID-19 severity including age, sex and presence of comorbidities including ischaemic heart disease, hypertension and diabetes mellitus did not associate with susceptibility to developing COVID-19.7 The degree of overlap between factors influencing susceptibility to COVID-19 vs. disease severity therefore appears to be limited (Figure 3).
Analyses of post-vaccination serology data showed that higher post-vaccination titres of anti-S antibodies associated with self-report of reactive symptoms following SARS-CoV-2 vaccination11 and were a correlate of protection against breakthrough COVID-19.12 We also identified several factors associating with lower anti-S antibody titres following a primary course of vaccination against SARS-CoV-2, including vaccination with ChAdOx1 nCoV-19 (Oxford AstraZeneca, ChAdOx1) vs. BNT162b2 (Pfizer), a shorter interval between vaccine doses, poor vs. excellent self-rated general health, immunodeficiency and use of immunosuppressant medications. Among a subset of 247 participants who were seronegative following their primary course of vaccination, administration of a single booster dose of mRNA vaccine was effective in achieving seroconversion in all but eight individuals, all of whom had a known immunodeficiency or were taking immunosuppressant medication.10
Analyses investigating incidence of SARS-CoV-2 infection in vaccinated participants showed that post-vaccination titres of anti-S antibodies were a correlate of protection against breakthrough COVID-19,12 and that risk of breakthrough disease was independently associated with younger vs. older age, lower vs. higher educational attainment, administration of ChAdOx1 vs. BNT182b2, and more vs. less frequent visits to indoor public places.13
A phase 3 trial-within-cohort study conducted in a subset of 6,200 COVIDENCE UK participants from December 2020 to June 2021 showed that implementation of a test-and-treat approach to correction of sub-optimal vitamin D status did not result in reduced incidence or severity of COVID-19.14
Health economic analyses of data from the cohort have demonstrated an independent association between incident COVID-19 and subsequently increased risk of reporting long-term sickness absence from work and household income being insufficient to meet basic needs.15 Given that socio-economic disadvantage is recognised to increase the risk of developing COVID-19,16 this finding raises the prospect that COVID-19 may generate a vicious cycle of impaired health and poor economic outcomes.
Risk factors for developing COVID-19 identified by COVIDENCE UK compared to risk factors for severe or fatal disease. Upward/downward arrows indicate increased/decreased risk, respectively.
DISCUSSION
What are the main strengths and weaknesses?
A major strength is that COVIDENCE UK was established specifically in response to the SARS-CoV-2 outbreak; thus, in contrast to previously established cohort studies, our questionnaires were tailored to capture potential risk factors and incident symptoms of COVID-19. Another strength of our study is that participants have given consent to be followed up for five years with full medical record linkage; thus if they die or fail to complete follow-up questionnaires, health outcomes will continue to be captured. Monthly follow-up reduces potential issues associated with poor recall of symptoms and health events that might arise with longer intervals between questionnaires. Our efforts to maintain participant engagement via monthly webinars, coupled with high degrees of public concern about the pandemic, are reflected in our low withdrawal rate (8%). In contrast to studies focusing exclusively on disease presenting to hospital, COVIDENCE UK is particularly well-positioned to identify risk factors for developing mild and moderate COVID-19, providing important insights into factors affecting disease transmission. Finally, the capacity of the cohort to support trial-within-cohort studies14 allows us to conduct phase 3 randomised controlled trials of interventions to prevent COVID-19 and other acute respiratory illnesses rapidly and efficiently.
The principal weakness of the cohort relates to under-representation of certain population groups, including younger adults, men, people with lower educational attainment and ethnic minorities: this may introduce collider bias,17 reduce the generalisability of our findings, and limit our power to detect risk factors for COVID-19 in these groups. However, we highlight that representativeness is not necessarily a barrier to addressing aetiological questions.18,19 Moreover, other groups at heightened risk of COVID-19 such as older adults and people with comorbidities are over-represented in the cohort, making us well placed to study them.
Can I get hold of the data? Where can I find out more?
Data can be accessed by contacting the corresponding author. Study findings will be presented at international conferences and published in peer-reviewed journals.
Data Availability
All data produced in the present work are contained in the manuscript
Author Contributions
HH and ARM wrote the first draft of the paper. All co-authors reviewed and contributed to the writing of the manuscript.
Funding
COVIDENCE UK is supported by funds granted by Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarch’s Foundation, the Karl R Pfleger Foundation, the AIM Foundation, HDR UK, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), Prof Barbara Boucher (personal donation) and Hyphens Pharma Ltd. MT was supported by a grant from the Rosetrees Trust and The Bloom Foundation (M771) until May 2021 and has been supported by the Barts and the London Charity since then.
Conflicts of interest
JS declares receipt of payments from Reach plc for news stories written about recruitment to, and findings of, the COVIDENCE UK study. RAL declares membership of the Welsh Government COVID19 Technical Advisory Group. AS declares research infrastructure report to the University of Edinburgh from ISCF/HDR UK. AS is a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group and its Standing Committee on Pandemics. He is also a member of the UK Government’s NERVTAG’s Risk Stratification Subgroup. ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares support for attending meetings from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd and Abiogen Pharma Ltd. ARM also declares receipt of a consultancy fee from DSM Nutritional Products Ltd and a speaker fee from the Linus Pauling Institute. ARM also declares participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195). ARM also declares unpaid work as a Programme Committee member for the Vitamin D Workshop. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd. All other authors declare that they have no competing interests.
Acknowledgements
We thank all COVIDENCE UK participants, and all our funders for their generous support.
Footnotes
Typographical error in Table 1 corrected
References
